Kenneth E. Hook
Impact in
- Oncology top 10%
- HER2/EGFR in Cancer Research
-
- Ubiquitin and proteasome pathways
- Cancer therapeutics and mechanisms
- PI3K/AKT/mTOR signaling in cancer
Papers in
-
- Cancer therapeutics and mechanisms 4
- Ubiquitin and proteasome pathways 3
- PI3K/AKT/mTOR signaling in cancer 2
- Oncology 7
- Cancer-related Molecular Pathways 3
- Cancer Treatment and Pharmacology 2
- HER2/EGFR in Cancer Research 2
- Co-authors
- Wilbur R. Leopold (5 shared papers)David W. Fry (4 shared papers)Ellen M. Dobrusin (1 shared paper)Jeff B. Smaill (2 shared papers)Annette M. Doherty (1 shared paper)Joseph A. Loo (1 shared paper)William A. Denny (2 shared papers)Paul R. Keller (1 shared paper)
- Journals
- Molecular Cancer Therapeutics (2 papers)Cancer Research (2 papers)Investigational New Drugs (2 papers)Osteoarthritis and Cartilage (1 paper)International Journal of Cancer (1 paper)
- Partner nations
- United StatesFranceNew Zealand
In The Last Decade
Kenneth E. Hook
15 papers receiving 770 citations
Peers
Comparison fields: 5 of 75
- Oncology 338
- Molecular Biology 415
- Rheumatology 89
- Pharmacology 82
- Organic Chemistry 138
Countries citing papers authored by Kenneth E. Hook
This map shows the geographic impact of Kenneth E. Hook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth E. Hook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth E. Hook more than expected).
Fields of papers citing papers by Kenneth E. Hook
This network shows the impact of papers produced by Kenneth E. Hook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth E. Hook. The network helps show where Kenneth E. Hook may publish in the future.
Co-authors
The 25 scholars most cited alongside Kenneth E. Hook, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1998 | 344 | |
| 2 | 2006 | 119 | |
| 3 | Binding of 14-3-3beta to the carboxyl terminus of Wee1 increases Wee1 stability, kinase activity, and G2-M cell population. | 2000 | 85 |
| 4 | 2012 | 77 | |
| 5 | 1995 | 55 | |
| 6 | 1985 | 37 | |
| 7 | 2013 | 31 | |
| 8 | 1995 | 13 | |
| 9 | In vivo and in vitro evaluation of the alkylating agent carmethizole. | 1991 | 10 |
| 10 | 2003 | 5 | |
| 11 | 1996 | 4 | |
| 12 | 1989 | 2 | |
| 13 | 2004 | 1 | |
| 14 | 2010 | 1 | |
| 15 | 2010 | 1 |
About Kenneth E. Hook
Kenneth E. Hook is a scholar working on Molecular Biology, Oncology, Cell Biology, Cancer Research and Organic Chemistry, having authored 15 papers that have together received 785 indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (4 papers), Microtubule and mitosis dynamics (3 papers), Cancer-related Molecular Pathways (3 papers), Ubiquitin and proteasome pathways (3 papers), Cancer Treatment and Pharmacology (2 papers), HER2/EGFR in Cancer Research (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). The work is most often cited by research in Oncology (338 citations), Molecular Biology (415 citations), Rheumatology (89 citations), Pharmacology (82 citations) and Organic Chemistry (138 citations). Kenneth E. Hook has collaborated with scholars based in United States, France and New Zealand. Frequent co-authors include Wilbur R. Leopold, David W. Fry, Ellen M. Dobrusin, Jeff B. Smaill, Annette M. Doherty, Joseph A. Loo, William A. Denny, Paul R. Keller, Alexander J. Bridges and James M. Nelson. Their work appears in journals such as Molecular Cancer Therapeutics, Cancer Research, Investigational New Drugs, Osteoarthritis and Cartilage and International Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.